4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aura Biosciences, Inc. (AURA) operates in the Biotechnology industry and is headquartered in Boston, United States with about 113 employees. Its market capitalization is roughly $724 million. In the fiscal year ended 2025-12-31, AURA reported $0M in revenue and ($106M) in net income.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($113M) | ($96M) | ($85M) | ($60M) | — |
| Net Income | ($106M) | ($87M) | ($76M) | ($59M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($35M) | ($27M) | ($28M) | ($29M) | ($29M) |
| Net Income | ($34M) | ($26M) | ($26M) | ($27M) | ($28M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $169M | $182M | $255M | $224M | — |
| Total Liabilities | $32M | $30M | $29M | $28M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AURA viewer.
About TickerBase · Data methodology & sources